Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesValue of Information Analyses of Economic Randomized Controlled Trials: The Treatment of Intermittent Claudication
Value in Health, 10/19/09
Hunink MGM et al. – The optimal study design for the treatment of intermittent claudication involves a randomized controlled trial collecting data on the quality–adjusted life expectancy and additional admission costs for 525 patients per treatment arm. The optimal sample size remained between 400 and 600 patients for a willingness–to–pay threshold between €30,000 and €100,000/quality–adjusted life–years, for even extreme assumptions about the study costs, and for a range of 3 to 7 years that future patients will benefit from the results of the proposed study.
Today in Economics of Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Medicare cracks down on false claims
Medical Economics, 11/02/09
2009 earnings survey: How do you compare
Medical Economics, 09/29/09
How sensitive is physician performance to alternative compensation schedules? Evidence from a large network of primary care clinics
Health Economics, 10/29/09
Sponsor
Article Search
Sponsor
Sponsor